Clinical trial assesses immunogenicity of a 2 + 1 DTPa vaccine in infants, revealing maternal antibodies affect antibody responses, suggesting implications for vaccination strategies.
We assessed the impact of maternally derived pertussis antibodies on infant responses to a 2 + 1 vaccine schedule (6 weeks, 12 weeks, and 12 months). Infants with baseline antibodies showed lower IgG responses following the primary vaccination series, but this did not impair booster responses at 4 years of age. Clinical Trials The study is registered on the Australian New Zealand Clinical Trials Registry – www.anzctr.org.au (Part 1: ACTRN12615000898550, Part 2: ACTRN12622001216707).
No takes yet. Share an insight, caveat, or question.
McAlister et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: